Literature DB >> 32383294

A biallelic pathogenic variant in the OGDH gene results in a neurological disorder with features of a mitochondrial disease.

Zheng Yie Yap1, Klaudia Strucinska1, Satoshi Matsuzaki1, Sukyeong Lee2, Yue Si3, Kenneth Humphries1, Mark A Tarnopolsky4, Wan Hee Yoon1.   

Abstract

2-Oxoglutarate dehydrogenase (OGDH) is a rate-limiting enzyme in the mitochondrial TCA cycle, encoded by the OGDH gene. α-Ketoglutarate dehydrogenase (OGDH) deficiency was previously reported in association with developmental delay, hypotonia, and movement disorders and metabolic decompensation, with no genetic data provided. Using whole exome sequencing, we identified two individuals carrying a homozygous missense variant c.959A>G (p.N320S) in the OGDH gene. These individuals presented with global developmental delay, elevated lactate, ataxia and seizure. Fibroblast analysis and modeling of the mutation in Drosophila were used to evaluate pathogenicity of the variant. Skin fibroblasts from subject # 2 showed a decrease in both OGDH protein and enzyme activity. Transfection of human OGDH cDNA in HEK293 cells carrying p.N320S also produced significantly lower protein levels compared to those with wild-type cDNA. Loss of Drosophila Ogdh (dOgdh) caused early developmental lethality, rescued by expressing wild-type dOgdh (dOgdhWT ) or human OGDH (OGDHWT ) cDNA. In contrast, expression to the mutant OGDH (OGDHN320S ) or dOgdh carrying homologous mutations to human OGDH p.N320S variant (dOgdhN324S ) failed to rescue lethality of dOgdh null mutants. Knockdown of dOgdh in the nervous system resulted in locomotion defects which were rescued by dOgdhWT expression but not by dOgdhN324S expression. Collectively, the results indicate that c.959A>G variant in OGDH leads to an amino acid change (p.N320S) causing a severe loss of OGDH protein function. Our study establishes in the first time a genetic link between an OGDH gene mutation and OGDH deficiency.
© 2020 SSIEM.

Entities:  

Keywords:  OGDH; TCA cycle; alpha-ketoglutarate dehydrogenase deficiency; genetic disease

Mesh:

Substances:

Year:  2020        PMID: 32383294      PMCID: PMC7647956          DOI: 10.1002/jimd.12248

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  43 in total

1.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm.

Authors:  Prateek Kumar; Steven Henikoff; Pauline C Ng
Journal:  Nat Protoc       Date:  2009-06-25       Impact factor: 13.491

2.  Mutations in the tricarboxylic acid cycle enzyme, aconitase 2, cause either isolated or syndromic optic neuropathy with encephalopathy and cerebellar atrophy.

Authors:  Metodi Dimitrov Metodiev; Sylvie Gerber; Laurence Hubert; Agnès Delahodde; Dominique Chretien; Xavier Gérard; Patrizia Amati-Bonneau; Marie-Christine Giacomotto; Nathalie Boddaert; Anna Kaminska; Isabelle Desguerre; Jeanne Amiel; Marlène Rio; Josseline Kaplan; Arnold Munnich; Agnès Rötig; Jean Michel Rozet; Claude Besmond
Journal:  J Med Genet       Date:  2014-10-28       Impact factor: 6.318

3.  P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in D. melanogaster.

Authors:  Koen J T Venken; Yuchun He; Roger A Hoskins; Hugo J Bellen
Journal:  Science       Date:  2006-11-30       Impact factor: 47.728

4.  Dietary supplement creatine protects against traumatic brain injury.

Authors:  P G Sullivan; J D Geiger; M P Mattson; S W Scheff
Journal:  Ann Neurol       Date:  2000-11       Impact factor: 10.422

5.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.

Authors:  P J Pollard; J J Brière; N A Alam; J Barwell; E Barclay; N C Wortham; T Hunt; M Mitchell; S Olpin; S J Moat; I P Hargreaves; S J Heales; Y L Chung; J R Griffiths; A Dalgleish; J A McGrath; M J Gleeson; S V Hodgson; R Poulsom; P Rustin; I P M Tomlinson
Journal:  Hum Mol Genet       Date:  2005-06-29       Impact factor: 6.150

6.  The severity of phenotype linked to SUCLG1 mutations could be correlated with residual amount of SUCLG1 protein.

Authors:  C Rouzier; S Le Guédard-Méreuze; K Fragaki; V Serre; J Miro; S Tuffery-Giraud; A Chaussenot; S Bannwarth; C Caruba; E Ostergaard; J-F Pellissier; C Richelme; C Espil; B Chabrol; V Paquis-Flucklinger
Journal:  J Med Genet       Date:  2010-08-07       Impact factor: 6.318

7.  Succinyl-CoA synthetase (SUCLA2) deficiency in two siblings with impaired activity of other mitochondrial oxidative enzymes in skeletal muscle without mitochondrial DNA depletion.

Authors:  Xiaoping Huang; Jirair K Bedoyan; Didem Demirbas; David J Harris; Alexander Miron; Simone Edelheit; George Grahame; Suzanne D DeBrosse; Lee-Jun Wong; Charles L Hoppel; Douglas S Kerr; Irina Anselm; Gerard T Berry
Journal:  Mol Genet Metab       Date:  2016-11-12       Impact factor: 4.797

8.  Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency.

Authors:  T Bourgeron; D Chretien; J Poggi-Bach; S Doonan; D Rabier; P Letouzé; A Munnich; A Rötig; P Landrieu; P Rustin
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Loss of Nardilysin, a Mitochondrial Co-chaperone for α-Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration.

Authors:  Wan Hee Yoon; Hector Sandoval; Sonal Nagarkar-Jaiswal; Manish Jaiswal; Shinya Yamamoto; Nele A Haelterman; Nagireddy Putluri; Vasanta Putluri; Arun Sreekumar; Tulay Tos; Ayse Aksoy; Taraka Donti; Brett H Graham; Mikiko Ohno; Eiichiro Nishi; Jill Hunter; Donna M Muzny; Jason Carmichael; Joseph Shen; Valerie A Arboleda; Stanley F Nelson; Michael F Wangler; Ender Karaca; James R Lupski; Hugo J Bellen
Journal:  Neuron       Date:  2016-12-22       Impact factor: 17.173

10.  Analysis of protein-coding genetic variation in 60,706 humans.

Authors:  Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2016-08-18       Impact factor: 49.962

View more
  7 in total

Review 1.  Targeting 2-oxoglutarate dehydrogenase for cancer treatment.

Authors:  Ling-Chu Chang; Shih-Kai Chiang; Shuen-Ei Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  Bi-allelic variants in OGDHL cause a neurodevelopmental spectrum disease featuring epilepsy, hearing loss, visual impairment, and ataxia.

Authors:  Zheng Yie Yap; Stephanie Efthymiou; Simone Seiffert; Karen Vargas Parra; Sukyeong Lee; Alessia Nasca; Reza Maroofian; Isabelle Schrauwen; Manuela Pendziwiat; Sunhee Jung; Elizabeth Bhoj; Pasquale Striano; Kshitij Mankad; Barbara Vona; Sanmati Cuddapah; Anja Wagner; Javeria Raza Alvi; Elham Davoudi-Dehaghani; Mohammad-Sadegh Fallah; Srinitya Gannavarapu; Costanza Lamperti; Andrea Legati; Bibi Nazia Murtaza; Muhammad Shahid Nadeem; Mujaddad Ur Rehman; Kolsoum Saeidi; Vincenzo Salpietro; Sarah von Spiczak; Abigail Sandoval; Sirous Zeinali; Massimo Zeviani; Adi Reich; Cholsoon Jang; Ingo Helbig; Tahsin Stefan Barakat; Daniele Ghezzi; Suzanne M Leal; Yvonne Weber; Henry Houlden; Wan Hee Yoon
Journal:  Am J Hum Genet       Date:  2021-11-19       Impact factor: 11.043

Review 3.  Toward an Understanding of the Structural and Mechanistic Aspects of Protein-Protein Interactions in 2-Oxoacid Dehydrogenase Complexes.

Authors:  Natalia S Nemeria; Xu Zhang; Joao Leandro; Jieyu Zhou; Luying Yang; Sander M Houten; Frank Jordan
Journal:  Life (Basel)       Date:  2021-04-29

4.  OGDH is involved in sepsis induced acute lung injury through the MAPK pathway.

Authors:  Yuewei Hao; Zheng Wang; Xinfang Wang; Wenming Zhan; Dianshui Wu
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

5.  Citrate Synthase and OGDH as Potential Biomarkers of Atherosclerosis under Chronic Stress.

Authors:  Ling-Bing Meng; Gai-Feng Hu; Meng-Jie Shan; Yuan-Meng Zhang; Ze-Mou Yu; Yun-Qing Liu; Hong-Xuan Xu; Li Wang; Tao Gong; De-Ping Liu
Journal:  Oxid Med Cell Longev       Date:  2021-09-08       Impact factor: 6.543

6.  Increasing Inhibition of the Rat Brain 2-Oxoglutarate Dehydrogenase Decreases Glutathione Redox State, Elevating Anxiety and Perturbing Stress Adaptation.

Authors:  Artem V Artiukhov; Anastasia V Graf; Alexey V Kazantsev; Alexandra I Boyko; Vasily A Aleshin; Alexander L Ksenofontov; Victoria I Bunik
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-31

Review 7.  Inter-Species Rescue of Mutant Phenotype-The Standard for Genetic Analysis of Human Genetic Disorders in Drosophila melanogaster Model.

Authors:  Alexandru Al Ecovoiu; Attila Cristian Ratiu; Miruna Mihaela Micheu; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.